“…Following, or in concert with, nucleic acid amplification, enzymes from the clustered regularly interspaced short palindromic repeats (CRISPR) platform have been employed for detection/diagnostics. CRISPR/Cas12 and Cas13 have nucleic acid cleavage abilities such that target nucleic acid interrogation and recognition leads to ectopic strand breaks of a secondary reporter molecule that can be detected by lateral flow assays (LFA) or fluorometry [ 8 , 9 , 10 , 11 , 12 , 13 ]. CRISPR/Cas9 has also been developed for diagnostics using solid-state nanopores, microfluidics, and LFA [ 14 , 15 , 16 , 17 , 18 ].…”